ECMO患者早期连续肾脏替代治疗随机对照试验
本研究为多中心随机开放试验,旨在评估ECMO患者早期启动CRRT能否降低30天死亡率。因可行性提前终止,共随机91例(早期组46例,常规组45例),30天死亡率早期组43.5% vs 常规组46.7%(HR 0.93, 95%CI 0.50-1.72; p=0.75),无显著差异。严重不良事件两组相似(25.6% vs 21.4%; OR 1.26, 95%CI 0.46-3.45; p=0.65)。
要点
- 早期CRRT未显著降低ECMO患者30天死亡率(HR 0.93, 95%CI 0.50-1.72)。
- 严重不良事件两组无显著差异(OR 1.26, 95%CI 0.46-3.45)。
- 试验因可行性提前终止,样本量不足,不能排除临床重要获益或危害。
核心结论
- ECMO患者早期启动CRRT compared with conventional initiation showed no evidence of a difference in 30-day mortality, but the trial was substantially underpowered and clinically important benefits or harms cannot be excluded.
研究设计与样本
- Investigator-initiated, multicentre, randomised, open clinical trial.
- Planned sample size 500 patients to provide 80% power and two-sided α 0.05 to detect a 20% relative reduction in 30-day mortality assuming 70% rate in usual care group.
- Study stopped early due to feasibility; 131 assessed for eligibility, 40 excluded, 91 randomised (46 early CRRT, 45 usual care).
- Primary endpoint: 30-day mortality; primary analysis unadjusted.
主要发现
- In intervention group, 35 patients (76.1%) received CRRT within 24 hours post-ECMO vs 15 patients (33.3%) in usual care group.
- Primary outcome occurred in 20 patients (43.5%) in early CRRT group and 21 patients (46.7%) in usual care group (HR 0.93, 95% CI 0.50 to 1.72; p=0.75).
- Serious adverse events: 11 (25.6%) vs 9 (21.4%); OR 1.26, 95% CI 0.46 to 3.45; p=0.65.
临床怎么用
- Early initiation of CRRT within 24 hours after ECMO did not show a significant reduction in 30-day mortality compared with conventional initiation.
- The underpowered results do not exclude clinically important benefits or harms, so routine early CRRT cannot be recommended based on this trial.
局限性
- Trial stopped early due to feasibility, resulting in substantially underpowered sample (91 vs planned 500).
- Open-label design.
- Primary analysis unadjusted.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat patients with severe cardiac and pulmonary failure but the complications of acute kidney injury and fluid overload are common. We aimed to determine whether the early initiation of continuous renal replacement therapy (CRRT) can reduce 30-day mortality in patients with ECMO. Methods The Evaluation of early CRRT intervention in patients with ECMO study was an investigator-initiated, multicentre, randomised, open clinical trial of patients undergoing ECMO who were randomly assigned to early initiation of CRRT (within 24 hours after ECMO) or conventionally indicated initiation of CRRT. All participants received standard diagnostic and therapeutic procedures. The primary endpoint was the 30-day mortality. A sample size of 500 patients was estimated to provide 80% power and a two-sided α of 0.05 to detect a 20% relative reduction in 30-day mortality assuming a rate of 70% in the usual care group. The primary analysis was unadjusted. Results The study stopped early due to feasibility. Of the 131 patients assessed for eligibility, 40 were excluded based on the inclusion and exclusion criteria. Of the 91 randomised patients, 46 were assigned to the early CRRT group and 45 were assigned to the usual care group. In the intervention group, 35 patients (76.1%) received CRRT within 24 hours post-ECMO implementation vs 15 patients (33.3%) in the usual care group. In the intention-to-treat analysis, the primary outcome occurred in 20 patients (43.5%) in the early CRRT group and 21 patients (46.7%) in the usual care group (HR 0.93, 95% CI 0.50 to 1.72; p=0.75). There was no significant difference in serious adverse events between the two groups (11 (25.6%) vs 9 (21.4%); OR 1.26, 95% CI 0.46 to 3.45; p=0.65). Conclusions Early implementation of CRRT in patients with ECMO showed no evidence of a difference in 30-day mortality compared with conventional initiation. However, the trial was substantially underpowered and clinically important benefits or harms cannot be excluded. Trial registration number NCT03549923 .
引用
- Open Heart:Effects of early continuous renal replacement therapy in critically ill patients requiring ECMO treatment: results of a randomised controlled trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。